Cardiac Progenitor Cells (CPCs) show great potential as a cell resource for restoring cardiac
function in patients affected by heart disease or heart failure. CPCs are proliferative and …

Despite the dramatic improvements in the management of patients with chronic heart failure
which have occurred over the last decades, some of them still exhaust conventional drug …

Background Allogeneic cardiac-derived progenitor cells (CPC) without immunosuppression
could provide an effective ancillary therapy to improve cardiac function in reperfused …

Oxidative stress-induced myocardial apoptosis and necrosis are critically involved in
ischemic infarction, and several sources of extracellular vesicles appear to be enriched in …

Pluripotent stem cells (PSC) can be used as a model to study cardiomyogenic differentiation.
In vitro modeling can reproduce cardiac development through modulation of some key …

Background Current treatments of chemotherapy-induced cardiomyopathy (CCM) are of
limited efficacy. We assessed whether repeated intravenous injections of human …

One of the drawbacks preventing the use of mesenchymal stem cells (MSCs) in clinical
practice is the heterogeneous nature of their cultures. MSC cultures are not homogeneously …

Highlights•Overview of analytics for characterization of stem cells' critical quality
attributes.•Highlight the main challenges for definition of stem cell potency.•Outline the role …

Human cardiac progenitor cells (hCPC) are considered a good candidate in cell therapy for
ischemic heart disease, demonstrating capacity to improve functional recovery after …

Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) are a valuable tool in stem cell
research due to their high proliferation rate, multi-lineage differentiation potential, and …